pralsetinib
Blueprint Medicines Reports $107M in Q4 Revenues Helped by Growing Ayvakit Sales
The company expects Ayvakit revenues to more than double in 2022, and projected sales in the range of $115 million to $130 million.
CHOP Researchers Find Gene Fusions are Harbingers of Aggressive Disease in Pediatric Thyroid Cancer
Premium
The findings could have treatment implications and encourage greater comprehensive genomic profiling in more young cancer patients.
European Commission Approves Roche's Gavreto for RET Fusion-Positive NSCLC
The conditional approval makes pralsetinib monotherapy available to advanced NSCLC patients in the European Union whose tumors harbor RET gene fusions.
Blueprint Medicines Reports $24.2M in Q3 Revenues Driven by Ayvakit Sales
Q3 revenues were down by 97 percent year over year because Blueprint's Q3 2020 revenues were bolstered by a licensing agreement with Roche for the RET inhibitor Gavreto.
Blueprint Medicines Q2 Revenues Increase More Than 200 Percent
In the second quarter, Blueprint reported $8.5 million in revenue from Ayvakit and $2.9 million in revenue from Gavreto.